

24 October 2024

## Osteopore steps up global expansion in Brazilian craniofacial market

### Highlights

- Osteopore signs exclusive 5-year Distribution Agreement with Medsite Equipamentos e Produtos Para Saude Ltda (Medsite) to distribute Osteopore's craniofacial products in Brazil.
- Osteopore seeks to leverage its global regulatory capabilities and success in North America with the US Food and Drug Administration (FDA).
- Osteopore has 24 months to complete product registration requirements with the Brazilian Health Regulatory Agency (Anvisa).
- The Agreement provides Osteopore with exposure to the \$6b p.a. Brazilian medical device market, while boosting its presence in the Latin American (LATAM) market.

Australian-Singaporean regenerative medicine company **Osteopore Limited** (ASX: **OSX**; **Osteopore** or **Company**) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the signing of an exclusive 5-year Distribution Agreement with Medsite Equipamentos e Produtos Para Saude Ltda (Medsite).

Under the agreement, Medsite will manage the regulatory filings in Brazil, a process expected to take approximately two years to complete. To enhance commercial adoption, Medsite will work with Zeiki Medical Produtos Medicos Ltda (Zeiki).



Established in 2006 under CEO and Founder Cristina Seixas, the Rio de Janeiro-based Zeiki supports circa 2,000 surgeries per annum. Zeiki sources innovative, high-quality and reliable products for the Brazilian market via leading global manufacturers. Zeiki's team collaborates with health operators, public entities, hospitals and clinicians across Brazil.

Zeiki is a member Abraidi (Associação Brasileira de Importadores e Distribuidores de Produtos para Saúde), of whose 300 members and associates supported circa 1.5 million surgeries (2022). In 2022, Brazil consumed USD \$3 billion in medical devices of which 39% was imported according to Abraidi.

The Agreement spans an initial 5-year term, coinciding with a projected 24-month regulatory period to complete Anvisa product registration requirements.

**Commenting on Osteopore's global expansion into Brazil and LATAM, CEO Dr Yujing Lim, said:**

"The decision to enter the Brazilian craniofacial market is a strategic one as it leverages the strength of US FDA and European Union CE Mark regulatory approvals. We are looking forward to introducing our craniofacial solutions to more patients in need.

"With the right partner, the Brazilian market represents a significant market opportunity. With our initial Brazilian engagement, we were strongly encouraged by the enthusiastic response of the Brazilian craniofacial surgical community," said Dr Lim.

The Brazilian medical device market is valued at more than \$6 billion annually, signifying LATAM's biggest healthcare market.

Brazilian regulatory clearance will enable Zeiki to leverage its extensive sales network and market knowledge to drive the adoption of Osteopore's products.

The Agreement will boost Osteopore's presence in LATAM and pave the way for market entry in countries including Colombia and Panama.



**ENDS**

*This announcement dated 24 October 2024 has been authorised for release to the ASX by the Board of Osteopore Limited.*

For more information, please contact:

**Dr Yujing Lim**

Chief Executive Officer

Osteopore Limited

E: [lim\\_yujing@osteopore.com](mailto:lim_yujing@osteopore.com)

**Isaac Stewart**

Media & Investor Relations

Purple

E: [istewart@purple.au](mailto:istewart@purple.au)



**About Osteopore Limited**

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

**Forward-Looking Statements**

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company's control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company's Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement. You are cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements in this announcement reflect views held only as at the date of this announcement.

This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.

